New function for an old enzyme: NEP deficient mice develop late-onset obesity

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-8

  Becker, Matthias ^a   Siems, Wolf Eberhard ^a   Kluge, Reinhart ^b   Gembardt, Florian ^c,d   Schultheiss, Heinz Peter ^e   Schirner, Michael ^f   Walther, Thomas ^c,d  

^a LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c UNIVERSITY OF HULL   (United Kingdom)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Mivenion GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANDOXATRIL; GLUCOSE; LIPID; MEMBRANE METALLOENDOPEPTIDASE;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CACHEXIA; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IMPAIRED GLUCOSE TOLERANCE; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PHYLOGENY; PROTEIN FUNCTION; WEIGHT REDUCTION; WILD TYPE; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; OBESITY; ONSET AGE; WEIGHT GAIN;

MUS;

ADIPOSE TISSUE; AGE OF ONSET; ANIMALS; BLOOD GLUCOSE; DISEASE MODELS, ANIMAL; MICE; MICE, KNOCKOUT; NEPRILYSIN; OBESITY; WEIGHT GAIN;

EID: 77958523183     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012793     Document Type: Article

References (38)

1. Finer N (2003) Obesity. Clin Med 3: 23-27.
2. Roth J, Qiang X, Marban SL, Redelt H, Lowell BC (2004) The obesity pandemic: where have we been and where are we going? Obes Res 12 Suppl 2: 88S-101S.
3. NHS - The Information Centre (2008) Statistics on Obesity, Physical Activity and Diet: England, January 2008.
4. Bell CG, Walley AJ, Froguel P (2005) The genetics of human obesity. Nat Rev Genet 6: 221-234.
5. Powell DR (2006) Obesity drugs and their targets: correlation of mouse knockout phenotypes with drug effects in vivo. Obes Rev 7: 89-108.
6. Harris RB, Hausman DB, Bartness TJ (2002) Compensation for partial lipectomy in mice with genetic alterations of leptin and its receptor subtypes. Am J Physiol Regul Integr Comp Physiol 283: R1094-1103.
7. Shirakami A, Toyonaga T, Tsuruzoe K, Shirotani T, Matsumoto K, et al. (2002) Heterozygous knockout of the IRS-1 gene in mice enhances obesity-linked insulin resistance: a possible model for the development of type 2 diabetes. J Endocrinol 174: 309-319.
8. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, et al. (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8: 75-79.
9. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, et al. (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8: 738-742.
10. Zemel MB, Shi H (2000) Pro-opiomelanocortin (POMC) deficiency and peripheral melanocortins in obesity. Nutr Rev 58: 177-180.
11. Scholzen TE, Luger TA (2004) Neutral endopeptidase and angiotensinconverting enzyme - key enzymes terminating the action of neuroendocrine mediators. Exp Dermatol 13 Suppl 4: 22-26.
12. Turner AJ, Nalivaeva NN (2007) New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection. Int Rev Neurobiol 82: 113-135.
13. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, et al. (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6: 143-150.
14. Davidson E, Coppey L, Lu B, Arballo V, Calcutt NA, et al. (2009) The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy. Exp Diabetes Res 2009: 431980.
15. Pankow K, Wang Y, Gembardt F, Krause E, Sun X, et al. (2007) Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 101: 875-882.
16. Siems W, Maul B, Krause W, Gerard C, Hauser KF, et al. (2000) Neutral endopeptidase and alcohol consumption, experiments in neutral endopeptidasedeficient mice. Eur J Pharmacol 397: 327-334.
17. Walther T, Stepan H, Pankow K, Becker M, Schultheiss HP, et al. (2004) Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide. Biol Chem 385: 179-184.
18. Chan DC, Barrett HP, Watts GF (2004) Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am J Cardiovasc Drugs 4: 227-246.
19. Adiels M, Olofsson SO, Taskinen MR, Boren J (2008) Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 28: 1225-1236.
20. Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404: 661-671.
21. Jaworski K, Ahmadian M, Duncan RE, Sarkadi-Nagy E, Varady KA, et al. (2009) AdPLA ablation increases lipolysis and prevents obesity induced by highfat feeding or leptin deficiency. Nat Med 15: 159-168.
22. Fischer HS, Zernig G, Hauser KF, Gerard C, Hersh LB, et al. (2002) Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide. J Mol Neurosci 18: 129-134.
23. Sturiale S, Barbara G, Qiu B, Figini M, Geppetti P, et al. (1999) Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc Natl Acad Sci U S A 96: 11653-11658.
24. Riviere PJ, Bueno L (1987) Origin of the stimulation of food intake by oral administration of enkephalinase inhibitors in sheep. Life Sci 41: 333-339.
25. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, et al. (1992) Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 10: 607-613.
26. Freemantle N, Holmes J, Hockey A, Kumar S (2008) How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract 62: 1391-1396.
27. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, et al. (2007) Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13: 803-811.
28. Poritsanos NJ, Mizuno TM, Lautatzis ME, Vrontakis M (2009) Chronic increase of circulating galanin levels induces obesity and marked alterations in lipid metabolism similar to metabolic syndrome. Int J Obes (Lond) 33: 1381-1389.
29. Inuzuka M, Tamura N, Yamada N, Katsuura G, Oyamada N, et al. (2010) Ctype natriuretic peptide as a new regulator of food intake and energy expenditure. Endocrinology 151: 3633-3642.
30. Pankow K, Schwiebs A, Becker M, Siems WE, Krause G, et al. (2009) Structural substrate conditions required for neutral endopeptidase-mediated natriuretic Peptide degradation. J Mol Biol 393: 496-503.
31. Walther T, Albrecht D, Becker M, Schubert M, Kouznetsova E, et al. (2009) Improved learning and memory in aged mice deficient in amyloid betadegrading neutral endopeptidase. PLoS One 4: e4590.
32. Cummings DE, Overduin J (2007) Gastrointestinal regulation of food intake. J Clin Invest 117: 13-23.
33. Lu B, Gerard NP, Kolakowski LF, Jr., Bozza M, Zurakowski D, et al. (1995) Neutral endopeptidase modulation of septic shock. J Exp Med 181: 2271-2275.
34. Kaye B, Brearley CJ, Cussans NJ, Herron M, Humphrey MJ, et al. (1997) Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril. Xenobiotica 27: 1091-1102.
35. McDowell G, Nicholls DP (2000) The Therapeutic Potential of Candoxatril, a Neutral Endopeptidase Inhibitor, in Humans. Cardiovascular Drug Reviews 18: 259-270.
36. Aust L, Dongowski G, Frenz U, Taufel A, Noack R (2001) Estimation of available energy of dietary fibres by indirect calorimetry in rats. Eur J Nutr 40: 23-29.
37. Winkler A, Rottmann M, Heder G, Hyytia P, Siems WE, et al. (1998) Gene expression and activity of specific opioid-degrading enzymes in different brain regions of the AA and ANA lines of rats. Biochim Biophys Acta 1406: 219-227.
38. Gross V, Milia AF, Plehm R, Inagami T, Luft FC (2000) Long-term blood pressure telemetry in AT2 receptor-disrupted mice. J Hypertens 18: 955-961.